Resources
- sort by:
- Relevance
- Date
- Popularity
- Human Genome Sciences Jumps on Glaxo Takeover Rumors
- Rumors of Glaxo's GSK takeover of Human Genome Sciences HGSI for $30/share have pushed the stock up considerably Tuesday. Human Genome Sciences stock was up $2.03 to $19.21 per share in afternoon trading with a gain of 11.79%. Aftermarket trading is up +0.46 to 19.66, another gain of 2.40%. I...
- External links 2009-08-26
- BREAKING NEWS: Groundbreaking lupus drug promising in second Phase III
- Human Genome Sciences and its partner GlaxoSmithKline revealed that the high dose of their experimental lupus therapy demonstrated a statistically superior response compared to placebo in a second late-stage trial, laying the groundwork for an FDA marketing application. Benlysta has helped transform HGS's prospects, and analysts were quick to...
- News items 2009-11-02
- Human Genome Sciences: Upgrade Precedes Data Report
- Thursday morning, J.P. Morgan raised its rating on Human Genome Sciences HGSI to Overweight, two trading days ahead of Monday's much anticipated top-line data from the second Phase III trial evaluating Benlysta in lupus. Previously, the firm had a neutral rating on the shares and a $14 target on...
- External links 2009-10-29
- Human Genome Sciences Raises $310m on Huge Share Price
- EP Vantage submits: Carpe diem appears to be the motto of the day for Human Genome Sciences HGSI, which is taking advantage of the huge share price rise it has experienced since announcing positive phase III data for its lupus drug, Benlysta, and raising up to $310m in a share...
- External links 2009-07-31
- UPDATED: Immunomedics Ignored, HGS Adored as Annual Rheumatology Confab Kicks Off
- The American College of Rheumatology's annual confab kicks off this weekend, and one item not on the menu is detailed Phase IIb data for Immunomedics and partner UCB's lupus drug epratuzumab. Meanwhile Human Genome Sciences’ lupus drug Benlysta looks to be the belle of the ball. by Trista Morrison
- Blog posts 2009-10-15
- Oxford Biomedica shines
- Another day and another big gain for a company developing a drug for Parkinson's disease. On Wednesday it was Phytopharm whose shares leapt 350 per cent following the release of promising early test results on its Cogane drug. Yesterday it was the turn of Oxford Biomedica , which jumped 58.1...
- News items 2009-10-15
- GSK steps along desired path of evolution
- Andrew Witty, chief executive of GlaxoSmithKline, said on Wednesday that the group's traditional core market of prescription medicines in developed countries may fall to just a quarter of total sales. He also said that further diversification would focus more on revenue growth than profit margins. Unveiling third-quarter results, Mr Witty,...
- News items 2009-10-28
- Lower Third Quarter Loss for Human Genome
- Zacks.com submits: Human Genome Sciences, Inc. HGSI reported third quarter net loss of $49 million or 32 cents per share, in-line with the Zacks Consensus Estimate. The company reported a net loss of $74.2 million or 50 cents in the year ago quarter. The lower net loss for...
- External links 2009-11-05
- << Previous
- page 1 of 1
- Next >>
Presented by American Express